Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895622 · ClinicalTrials.gov registry record · Phase 2
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 20
- Study locations
NCT00895622 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 244 participants, above the 178-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00895622, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy, may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether observation is more effective than radiation therapy in treating patients with meningioma. PURPOSE: This phase II trial is studying observation to see how well it works compared with radiation therapy in treating patients with grade I, grade II, or grade III meningioma.
Conditions Studied
Interventions
- RADIATION 54 Gy radiotherapy
- RADIATION 60 Gy radiotherapy
Study Locations (20)
Arizona
- Arizona Oncology Services Foundation - Phoenix
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic Scottsdale - Scottsdale
Georgia
- Emory Crawford Long Hospital - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
- Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah
Kansas
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center - Kansas City
- Kansas City Cancer Centers - Southwest - Overland Park
- CCOP - Kansas City - Prairie Village
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- University of Florida Shands Cancer Center - Gainesville
- Baptist-South Miami Regional Cancer Program - Miami
Connecticut
- Yale Cancer Center - New Haven
Idaho
- Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center - Boise
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2009-06 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00895622
The ClinicalTrials.gov registry entry for NCT00895622 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (37% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which 54 Gy radiotherapy is the first listed.
NCT00895622 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Arizona, Georgia, Kansas.
Frequently Asked Questions
What is clinical trial NCT00895622 about?
NCT00895622 is a clinical study titled "Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma". RATIONALE: Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as 3-dimensional conformal radiation therapy and intensity-modulated radiation therap...
What is the current status of trial NCT00895622?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2009-06. Estimated completion is 2023-08-15.
What conditions does trial NCT00895622 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00895622?
The interventions under investigation include: 54 Gy radiotherapy (RADIATION), 60 Gy radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00895622?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00895622 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.